GlassScriptPhysician profile
Karen E Springer
NPI 1225035421
$8,117.89
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,310 · 2022: $4,253 · 2023: $830 · 2024: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,481 · Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,481.07 |
| Food and Beverage | $1,073.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,069.26 | 2022 | |
| Abbott Laboratories | $1,680.09 | 2024 | Infinity |
| Abbvie INC. | $1,382.24 | 2021-2023 | |
| Biogen, INC. | $272.21 | 2021-2023 | Spinraza |
| Biohaven Pharmaceutical Holding Company LTD. | $254.87 | 2022 | |
| Inspire Medical Systems, INC. | $211.66 | 2022-2024 | Inspire |
| Jazz Pharmaceuticals INC. | $189.77 | 2021-2023 | |
| Acadia Pharmaceuticals INC | $186.80 | 2021-2023 | Nuplazid |
| Janssen Pharmaceuticals, INC | $158.81 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $131.30 | 2021 | |
| Livanova USA, INC. | $128.84 | 2021-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $118.76 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $112.69 | 2021-2023 | Austedo Xr, Austedo |
| Lilly USA, LLC | $80.42 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $75.71 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.